UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of thrombosis and thrombolysis, ISSN 0929-5305, 8/2011, Volume 32, Issue 2, pp. 183 - 187
Medicine & Public Health | Hematology | Cardiology | Acute coronary syndrome | Ant-Xa activity | Apixaban | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Pyridones - pharmacokinetics | Humans | Middle Aged | Male | Factor Xa - metabolism | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Pyridones - administration & dosage | Pyrazoles - administration & dosage | Blood Coagulation Tests - methods | Female | Aged | Anticoagulants - pharmacokinetics | Pyrazoles - pharmacokinetics | Medical colleges | Safety regulations | Analysis | Cardiac patients | Liquid chromatography | Coronary heart disease | Mass spectrometry | Index Medicus
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 04/2010, Volume 103, Issue 4, pp. 815 - 825
fondaparinux | rivaroxaban | Clotting assays | venous thromboembolism | pharmacodynamics | Factor Xa inhibitor | New Technologies, Diagnostic Tools and Drugs | Rivaroxaban | Pharmacodynamics | Venous thromboembolism | Fondaparinux | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Cardiology. Vascular system | Hematologic and hematopoietic diseases | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Blood and lymphatic vessels | Platelet diseases and coagulopathies | Predictive Value of Tests | Factor Xa Inhibitors | Humans | Prothrombin Time | Fibrinolytic Agents - blood | Thiophenes - administration & dosage | Blood Coagulation Tests - standards | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Dose-Response Relationship, Drug | Time Factors | Reproducibility of Results | Thrombelastography | Administration, Oral | Morpholines - administration & dosage | Morpholines - pharmacology | Thiophenes - pharmacology | Calibration | Polysaccharides - pharmacology | Drug Monitoring - standards | Fibrinolytic Agents - pharmacology | Blood Coagulation - drug effects | Partial Thromboplastin Time | Fibrinolytic Agents - administration & dosage | Thrombin - metabolism
Journal Article
The American heart journal, ISSN 0002-8703, 2010, Volume 160, Issue 4, pp. 635 - 641.e2
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Heart | Cardiac dysrhythmias | Biological and medical sciences | Myocarditis. Cardiomyopathies | Medical sciences | Coronary heart disease | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Thiazoles - therapeutic use | Atrial Fibrillation - physiopathology | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Thrombolytic Therapy - methods | Electrocardiography | Female | Myocardial Infarction - physiopathology | Retrospective Studies | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Myocardial Infarction - complications | Stroke - etiology | Myocardial Infarction - drug therapy | Aged | Warfarin | Care and treatment | Comparative analysis | Atrial fibrillation | Heart attack | Women | Anticoagulants | Cardiac arrhythmia | Hepatitis | Nonsteroidal anti-inflammatory drugs | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 11/2012, Volume 108, Issue 5, pp. 876 - 886
Recommendations | rivaroxaban | practical management | anticoagulant | Consensus Paper | Rivaroxaban | Anticoagulant | Practical management | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Male | Thiophenes - administration & dosage | Dabigatran | Warfarin - administration & dosage | Venous Thromboembolism - prevention & control | Benzimidazoles - administration & dosage | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Blood Loss, Surgical - prevention & control | Stroke - prevention & control | Venous Thrombosis - drug therapy | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Clinical Trials as Topic | Anticoagulants - adverse effects | Pregnancy | Practice Guidelines as Topic | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | recommendations
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2413 - 2424
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Humans | Middle Aged | Male | Rivaroxaban - adverse effects | Female | Factor Xa - therapeutic use | Prothrombin - metabolism | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Antidotes - pharmacology | Peptide Fragments - metabolism | Double-Blind Method | Administration, Oral | Recombinant Proteins - pharmacology | Factor Xa - metabolism | Protein Precursors - metabolism | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Blood Coagulation - drug effects | Factor Xa - pharmacology | Factor Xa Inhibitors - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Antidotes - therapeutic use | Treatment outcome | Usage | Analysis | Clinical trials | Anticoagulants (Medicine) | Dosage and administration | Hemorrhage | Risk factors | Prevention | Anticoagulants | Side effects | Inhibitor drugs | Prothrombin | Thrombin | Thrombosis | Index Medicus | Abridged Index Medicus
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 10/2013, Volume 111, Issue 2, pp. 240 - 248
Anti-xa | Blood coagulation tests | Anticoagulant agents | Multicenter study | Apixaban | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Predictive Value of Tests | Reproducibility of Results | Factor V - metabolism | Factor Xa Inhibitors | Laboratory Proficiency Testing | Humans | Prothrombin Time | Blood Coagulation Tests - standards | Drug Monitoring - methods | Pyridones - blood | Anticoagulants - blood | Drug Monitoring - standards | Reference Standards | Blood Coagulation - drug effects | Partial Thromboplastin Time | Pyrazoles - blood | France | Prothrombin - metabolism | Observer Variation
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 12/2010, Volume 104, Issue 6, pp. 1263 - 1271
prothrombin time | anti-Xa activity | Factor Xa inhibitor | international normalised ratio | Apixaban | New Technologies, Diagnostic Tools and Drugs | Anti-Xa activity | International normalised ratio | Prothrombin time | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Predictive Value of Tests | Pyrazoles - therapeutic use | Reproducibility of Results | Factor Xa Inhibitors | Humans | Prothrombin Time | Anticoagulants - therapeutic use | Drug Monitoring - methods | Morpholines - blood | Thiophenes - blood | Pyridones - blood | Venous Thromboembolism - drug therapy | Anticoagulants - blood | Venous Thromboembolism - blood | Dose-Response Relationship, Drug | International Normalized Ratio | Rivaroxaban | Blood Coagulation - drug effects | Pyrazoles - blood | Blood Coagulation Tests | Isoxazoles - blood | Pyridones - therapeutic use | Clinical Trials, Phase II as Topic
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 03/2005, Volume 3, Issue 3, pp. 514 - 521
antithrombotic activity | oral anticoagulant | Factor Xa inhibitor | Oral anticoagulant | Antithrombotic activity | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Rabbits | Factor Xa Inhibitors | Species Specificity | Venous Thrombosis - drug therapy | Humans | Morpholines - pharmacology | Rats | Dose-Response Relationship, Drug | Serine Proteinase Inhibitors - therapeutic use | Fibrinolytic Agents - pharmacology | Rivaroxaban | Animals | Thiophenes | Fibrinolytic Agents - therapeutic use | Blood Coagulation Tests | Inhibitory Concentration 50 | Venous Thrombosis - prevention & control | Thromboplastin - metabolism | Serine Proteinase Inhibitors - pharmacology | Disease Models, Animal | Index Medicus
Journal Article
Circulation research, ISSN 0009-7330, 09/2012, Volume 111, Issue 8, pp. 1069 - 1078
heparin | thrombosis | rivaroxaban | factor Xa inhibitors | apixaban | edoxaban | warfarin | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Biological and medical sciences | Vertebrates: cardiovascular system | Animals | Factor Xa Inhibitors | Anticoagulants - pharmacology | Humans | Drug Design | Pyridines - pharmacology | Thiazoles - pharmacology | Thrombosis - drug therapy | Thrombosis - blood | Pyridones - pharmacology | Pyrazoles - pharmacology | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 25, pp. 2471 - 2472
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Hemorrhage - drug therapy | Factor Xa Inhibitors - adverse effects | Humans | Female | Male | Factor Xa - therapeutic use | Anticoagulants (Medicine) | Dosage and administration | Antidotes | Research | Studies | Plasma | Anticoagulants | Side effects | Inhibitor drugs | Fibrillation | Thrombin | Antagonists | Drug development | Hemorrhage | Drug dosages | Vitamin K | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2016, Volume 375, Issue 12, pp. 1131 - 1141
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Prospective Studies | Humans | Male | Intracranial Hemorrhages - drug therapy | Recombinant Proteins - adverse effects | Enoxaparin - adverse effects | Cardiovascular Diseases - complications | Intracranial Hemorrhages - diagnosis | Rivaroxaban - adverse effects | Aged, 80 and over | Female | Factor Xa - therapeutic use | Gastrointestinal Hemorrhage - drug therapy | Factor Xa - adverse effects | Pyrazoles - adverse effects | Acute Disease | Gastrointestinal Hemorrhage - chemically induced | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Thrombosis - etiology | Factor Xa Inhibitors - adverse effects | Intracranial Hemorrhages - chemically induced | Factor Xa Inhibitors - metabolism | Aged | Hemorrhage - chemically induced | Infusions, Intravenous | Pyridones - adverse effects | Care and treatment | Anticoagulants (Medicine) | Research | Management | Hemorrhage | Patients | Enzymes | Hemostasis | Coagulation | Cardiovascular diseases | Drug therapy | Bleeding | Index Medicus | Abridged Index Medicus
Journal Article